Cardiology · AnticoagulationTrial Updateclinicalmid-term

SINGLE-AF Trial Evaluates DOACs in Intermediate Stroke Risk Atrial Fibrillation Patients

Importance8/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/9/2026, 12:33:08 AM

Assessment confidence: 62% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The SINGLE-AF trial is pivotal in assessing the efficacy of DOACs for patients with intermediate stroke risk, a previously underrepresented group in anticoagulation therapy. Positive results could significantly shift treatment guidelines and enhance the market position of DOACs, impacting overall sales and competitive dynamics in the anticoagulant sector. Regulatory context from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) supports the near-term read. Assessment grounded in 5 ranked evidence items (2 high-relevance).

Strategic Assessment

Positive outcomes could expand the use of DOACs, impacting sales and market share against other anticoagulant therapies. The strongest clinical anchor is The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF) (ClinicalTrials.gov), entity match (patients with atrial fibrillation). In cardiology, 3 regulatory and 0 competitive items passed relevance filtering for patients with atrial fibrillation.

Competitive Pressure

The most relevant competitive pressure comes from Results may influence treatment guidelines and market positioning for DOACs like apixaban and rivaroxaban in this patient population..

Regulatory Outlook

Regulatory risk is concentrated around Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA). Sub-indication match (cardiology).

Key Risks

Elevated medium regulatory exposure for patients with atrial fibrillation could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.
Regulatory risk from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) could weigh on patients with atrial fibrillation through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

If the trial demonstrates that DOACs are effective for this patient population, it could lead to increased adoption and sales, thereby enhancing market share against traditional anticoagulants.
Upside for patients with atrial fibrillation may improve if Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA) delivers favorable follow-through.
Positive outcomes could expand the use of DOACs, impacting sales and market share against other anticoagulant therapies.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and publication of findings, particularly regarding the primary endpoint of adverse clinical events.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026
FDAhigh relevance
Sub-indication match (cardiology)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes
FDAlow relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Condition-Specific Meeting Reports and Other Information Related to Patients' Experience
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA Alerts Health Care Providers to Cases of Neurologic Complications from General Anesthesia Linked to Genetic Variant in Patients of Maternal Venezuelan Ancestry
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Opportunities for patients and the public to be involved in the work of the MHRA
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)
ClinicalTrials.govmedium relevance
Entity match (patients with atrial fibrillation)
FDA document
View source
Evaluation of EXL01, New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
The Effect of Superficial Cervical Block Application on Postoperative Opioid Consumption in Patients Undergoing Anterior Cervical Discectomy Surgery
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Biogen's Felzartamab Study Targets Isolated Microvascular Inflammation in Kidney Transplant Patients
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
Psilocybin Shows Promise in Preventing Relapse in Alcohol Use Disorder with Depression
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Safety and efficacy of ashwagen (a standardized withania somnifera extract) in stress and anxiety with hypertension and associated cardiometabolic risk factors: a randomized, placebo-controlled trial.
PubMedhigh relevance
Sub-indication match (cardiology)
FDA document
View source
Cost-effectiveness analysis of apixaban compared with other oral anticoagulants for the treatment of non-valvular atrial fibrillation in Belgian healthcare setting.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Wrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of sub-anesthetic doses of esketamine on immune function and postoperative negative emotions in acoustic neuroma patients: a randomized clinical trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

patients with atrial fibrillation

Commercial impact

high

If the trial demonstrates that DOACs are effective for this patient population, it could lead to increased adoption and sales, thereby enhancing market share against traditional anticoagulants.

Regulatory impact

medium

The trial's outcomes may influence future regulatory guidelines and recommendations for anticoagulation therapy in patients with intermediate stroke risk, potentially leading to label expansions for DOACs.

What to watch

Monitor trial results and publication of findings, particularly regarding the primary endpoint of adverse clinical events.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.